FUT1

Five specialized treatment centers being qualified across the U.S. to minimize travel burden on eligible patients and their families Orchard Assist patient services program to provide individualized support throughout the treatment process Lenmeldy wholesale acquisition cost of $4.25 million for one-time treatment reflects its clinical, economic and societal value Innovative outcomes- and value-based agreements are being offered to both private and government insurers to ensure broad, expedient and sustainable reimbursed access TOKYO, LONDON and BOSTON, March 20, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced the details of its U.S. commercial launch of Lenmeldy™ (atidarsagene autotemcel), formerly known as OTL-200, the first FDA-approved therapy for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile, (PSEJ), or early symptomatic early juvenile (ESEJ)—collectively referred to as early-onset—metachromatic leukodystrophy (MLD). MLD is an ultra-rare, rapidly progressive, irreversible and ultimately fatal neurometabolic disease that affects approximately one in 100,000 live births, which is estimated to be fewer than 40 children annually in the U.S. It is caused by a mutation in the gene responsible for encoding the enzyme arylsulfatase A (ARSA) leading to neurological damage and developmental regression. In the most severe form of MLD, babies develop normally but in late infancy start to rapidly lose the ability to walk, talk and interact with the world around them. These children eventually deteriorate into a vegetative state, which may require 24-hour intensive care, and the majority pass away within five years of symptom onset, creating an enormous emotional and financial burden on the family. Prior to Lenmeldy, there were no treatment options in the U.S. for early-onset MLD beyond supportive and end-of-life care. Lenmeldy aims to correct the underlying genetic cause of MLD by inserting one or more functional copies of the human ARSA gene ex vivo (outside the body) into the genome of a patient’s own hematopoietic stem cells (HSCs) using a lentiviral vector. The genetically repaired cells are infused back into the patient, where, once engrafted, they differentiate into multiple cell types, some of which migrate across the blood-brain barrier into the central nervous system and express the functional enzyme. Prior to treatment, patients must undergo high-dose chemotherapy, a process that removes cells from the bone marrow so they can be replaced with the modified cells in Lenmeldy. This approach has the potential to restore enzymatic function to stop or slow disease progression with a single treatment. “Lenmeldy is truly a paradigm-shifting medicine and has the potential to stop or slow the progression of this devastating childhood disease with a single treatment, particularly when administered prior to the onset of symptoms,” said Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer of Orchard Therapeutics. “We are committed to enabling broad, expedient and sustainable access to this important therapy for eligible patients with early-onset MLD in the U.S.” “The launch of Lenmeldy in the United States will build on our success delivering personalized gene therapies to eligible children with MLD throughout Europe and the Middle East by utilizing a similar commercial strategy and infrastructure,” said Frank Thomas, president and chief operating officer of Orchard Therapeutics. “We are confident in the potential long-term clinical outcomes of Lenmeldy and will continue to work with public and private payers to structure outcomes-based and other types of innovative reimbursement models that appropriately balance the needs of patients and families for adequate access, health care systems for affordability, as well as support future research and development of treatments for ultra-rare diseases like MLD.” Clinical data supporting U.S. approval of Lenmeldy The FDA approval of Lenmeldy is based on data from 37 pediatric patients with early-onset MLD, enrolled in two single-arm, open-label clinical studies or treated under European expanded access frameworks, who received a one-time administration of the gene therapy and compared with natural history data. All treated patients were administered Lenmeldy and subsequently monitored at Ospedale San Raffaele in Milan, Italy. All children with PSLI MLD who were treated with Lenmeldy were alive at 6 years of age, compared to only 58% of children in the natural history group. At 5 years of age, 71% of treated children were able to walk without assistance and 85% of the children treated had normal language and performance IQ scores, which has not been reported in untreated children. In addition, children with PSEJ and ESEJ MLD showed slowing of motor and/or cognitive disease. The most common side effects of Lenmeldy are fever and low white blood cell count, mouth sores, respiratory infections, rash, medical line infections, viral infections, fever, gastrointestinal infections and enlarged liver. After infusion with Lenmeldy, patients should be monitored for neutrophil counts and risk of delayed platelet engraftment until engraftment has been achieved. Treatment with Lenmeldy may be associated with formation of blood clots or a type of swelling of brain tissues known as encephalitis. There is a potential risk of blood cancer associated with this type of treatment; however, no cases have been seen in patients treated with Lenmeldy. Patients receiving this therapy should have life-long monitoring for hematologic malignancies, including a complete blood count (with differential) annually and integration site analysis, as warranted, for at least 15 years after treatment. Please see below for additional details and Important Safety Information. With more than 12 years of follow-up in the earliest treated patients (median of 6.76 years), Lenmeldy is launching with the longest duration of follow-up available at the time of approval for a gene therapy in the U.S. to date. Wholesale acquisition cost reflects potential value of one-time, personalized gene therapies Orchard Therapeutics has set the wholesale acquisition cost (WAC) of Lenmeldy in the U.S. at $4.25 million which is reflective of the value the therapy may deliver to eligible patients and their families, as well the potential long-term impact treatment may have on overall healthcare utilization, minimization of productivity loss for caregivers, and life opportunities for patients. The WAC was determined following the completion of a comprehensive Health Technology Assessment (HTA) by the independent, non-profit organization, the Institute for Clinical and Economic Review (ICER) which determined the health benefit price benchmark (HBPB) for Lenmeldy to be up to $3.94 million at the $150,000 per Equal Value Life Year (evLY) threshold from a modified societal perspective. “The value of Lenmeldy has been recognized by several HTA authorities around the world, including in the U.S. by ICER, which determined Lenmeldy to have the highest value-based price for any treatment it has evaluated to date,” said Bennett Smith, senior vice president and general manager of North America at Orchard Therapeutics. “MLD places an enormous emotional and economic burden on families and caregivers—who face substantial wage loss and added expenses each year as the disease progresses—all while dealing with the unquantifiable anguish of losing their child. HSC gene therapy has the potential to offer a transformative impact on devastating genetic diseases not well addressed by other therapeutic modalities, and we will continue to ensure society reaps the benefits from the anticipated value these therapies may deliver to eligible children and their families.” Enabling timely access and reimbursement Lenmeldy is launching with an unprecedented amount of follow-up data, providing support for the potential long-term durability of treatment effect. Recognizing the need to establish innovative payment structures for one-time durable therapies, Orchard Therapeutics is working collaboratively with commercial and government payers to offer outcomes- and value-based agreements intended to ensure timely access by sharing risk between the payer and manufacturer. Finalizing qualification of specialized treatment centers across the U.S. Lenmeldy is being made available to eligible patients through a network of Qualified Treatment Centers (QTCs) in key regions throughout the United States to minimize the travel burden on patients and their families. Five treatment centers with specialized expertise in transplant and the treatment of neurometabolic diseases, like MLD, are being activated. One of those centers, the M Health Fairview Masonic Children’s Hospital in Minnesota, is in the final stages of qualification. Several eligible children with MLD from the U.S. have already been treated at the center on a compassionate use basis with drug product supplied by Orchard Therapeutics manufactured using commercial processes. Four additional regional centers geographically dispersed throughout the United States, including Children’s Healthcare of Atlanta, Children's Hospital of Philadelphia, Texas Children’s Hospital, and UCSF Benioff Children’s Hospital San Francisco, are in the process of becoming fully qualified. Supporting patients and their families throughout the treatment process Orchard Therapeutics’ patient support program, Orchard Assist, will offer individualized support for eligible patients and their caregivers who enroll in the program throughout the treatment process. Experienced case managers with success supporting patients and their families with both private and public insurance are available to assist in accessing Lenmeldy. For more information, please visit . Expanding newborn screening efforts As with many rare, life-threatening pediatric diseases, early detection and diagnosis is key to ensuring the best possible outcomes for patients, and Orchard Therapeutics supports efforts to expand newborn screening (NBS) for diseases like MLD which meet Wilson and Jungner criteria. Currently, ten prospective NBS studies for MLD are active throughout the U.S., Europe and the Middle East, with approximately 275,000 newborns screened to date. The data from these studies provide critical evidence to support applications for universal screening of MLD in the U.S. and around the world. Utilizing results from such studies, a multi-stakeholder working group is finalizing a nomination to add MLD to the U.S. Recommended Uniform Screening Panel (RUSP), a national guideline for NBS comprising a list of medical conditions for which the federal government recommends all newborns receive screening. States use the RUSP to help them decide which conditions to include in their NBS panels. Based on current timelines and assumptions, Orchard Therapeutics expects the nomination will be submitted in mid-year 2024. About MLD MLD is a rare and life-threatening inherited disease of the body’s metabolic system estimated to occur in approximately one in every 100,000 live births based on existing literature. MLD is caused by a mutation in the arylsulfatase-A (ARSA) gene that results in the accumulation of sulfatides in the brain and other areas of the body, including the liver, gallbladder, kidneys, and/or spleen. Over time, the nervous system is damaged, leading to neurological problems such as motor, behavioral and cognitive regression, severe spasticity, and seizures. Patients with MLD gradually lose the ability to move, talk, swallow, eat and see. In its late infantile form, mortality at five years from onset is estimated at 50 percent and 44 percent at 10 years for juvenile patients.i About Lenmeldy Lenmeldy™ (atidarsagene autotemcel), formerly known as OTL-200, is the only approved therapy in the U.S. for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ) or early-symptomatic early juvenile (ESEJ) metachromatic leukodystrophy (MLD). For additional details about Lenmeldy, please refer to the full Prescribing Information. In Europe, Lenmeldy is known as Libmeldy®, where it has been approved by the European Commission (EC), UK Medicines and Healthcare products Regulatory Agency (MHRA), and Swiss Agency for Therapeutic Products (Swissmedic). For more information about Libmeldy, please see the Summary of Product Characteristics (SmPC) available on the EMA website. The program was originated by and developed in partnership with the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy. INDICATION LENMELDY™ (atidarsagene autotemcel) is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ), or early symptomatic early juvenile (ESEJ) metachromatic leukodystrophy (MLD). IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Thrombosis and Thromboembolic Events: Treatment with LENMELDY may increase the risk of thrombosis and thromboembolic events. A child with PSEJ MLD died after experiencing a left hemisphere cerebral infarction secondary to a thrombotic event in a large blood vessel approximately 1 year after treatment with LENMELDY. Evaluate the risk factors for thrombosis prior to and after LENMELDY infusion according to best clinical practice. Encephalitis: Treatment with LENMELDY may increase the risk of encephalitis. A child with ESEJ developed a serious event of encephalitis after treatment with LENMELDY. The etiology of this event is unclear but attribution to LENMELDY cannot be ruled out. Treatment with LENMELDY may trigger a relapsing-remitting pattern of disease progression. No other events related to encephalitis have been reported during the clinical development of LENMELDY. Monitor children for signs or symptoms of encephalitis after LENMELDY treatment. Serious Infection: In the period between start of conditioning and within 1 year after LENMELDY treatment, severe Grade 3 infections occurred in 39% of all children (21% bacterial, 5% viral, 5% bacterial and viral or bacterial and fungal, and 8% unspecified). Grade 3 febrile neutropenia developed within 1 month after LENMELDY infusion in 82% of children. In the event of febrile neutropenia, monitor for signs and symptoms of infection and manage with broad-spectrum antibiotics, fluids, and other supportive care as medically indicated. Monitor children for signs and symptoms of infection after myeloablative conditioning and LENMELDY infusion and treat appropriately. Administer prophylactic antimicrobials according to best clinical practice. Veno-Occlusive Disease: Three children (8%) treated in clinical trials of LENMELDY developed veno-occlusive disease (VOD) with one Grade 4 SAE and two Grade 3 AEs. None of these three events met Hy’s Law criteria. Monitor children for signs and symptoms of VOD including liver function tests in all children during the first month after LENMELDY infusion. Consider prophylaxis for VOD with anti-thrombotic agents based on risk factors for VOD and best clinical practice. Delayed Platelet Engraftment (DPE): DPE has been observed with LENMELDY treatment. Bleeding risk is increased prior to platelet engraftment and may continue after engraftment in children with prolonged thrombocytopenia. In clinical trials of LENMELDY, 4 (10%) children had delayed platelet engraftment after day 60 (range day 67-109), with 3 children requiring platelet transfusions until engraftment occurred. Patients should be informed of the risk of bleeding until platelet recovery has been achieved. Monitor patients for thrombocytopenia and bleeding until platelet engraftment and recovery are achieved. Neutrophil Engraftment Failure: There is a potential risk of neutrophil engraftment failure after treatment with LENMELDY. Monitor neutrophil counts until engraftment has been achieved. If neutrophil engraftment failure occurs in a child treated with LENMELDY, provide rescue treatment with the unmanipulated back-up collection of CD34+ cells. Insertional Oncogenesis: There is a potential risk of LVV-mediated insertional oncogenesis after treatment with LENMELDY. Children treated with LENMELDY may develop hematologic malignancies and should be monitored life-long. Monitor for hematologic malignancies with a complete blood count (with differential) annually and integration site analysis as warranted for at least 15 years after treatment with LENMELDY. In the event that a malignancy occurs, contact Orchard Therapeutics at 1-888-878-0185 for reporting and to obtain instructions on collection of samples for testing. Hypersensitivity Reactions: The dimethyl sulfoxide (DMSO) in LENMELDY may cause hypersensitivity reactions, including anaphylaxis which is potentially life-threatening and requires immediate intervention. Hypersensitivity including anaphylaxis can occur in children with and without prior exposure to DSMO. Monitor for hypersensitivity reactions during infusion and after infusion. Anti-Retroviral Use: Children should not take prophylactic HIV anti-retroviral medications for at least one month prior to mobilization, or for the expected duration of time needed for the elimination of the medications. Anti-retroviral medications may interfere with the manufacturing of LENMELDY. If a child requires antiretrovirals for HIV prophylaxis, initiation of LENMELDY treatment should be delayed until confirmation of a negative test for HIV. Interference With Serology Testing: Due to the likelihood of a false-positive test for HIV, children who have received LENMELDY should not be screened for HIV infection using a PCR-based assay. USE IN SPECIFIC POPULATIONS Females and Males of Reproductive Potential Pregnancy Testing As a precautionary measure, a negative serum pregnancy test must be confirmed prior to the start of mobilization, and reconfirmed prior to conditioning procedures, and before administration of LENMELDY in females of childbearing potential. Contraception Consult the Prescribing Information of the mobilization and conditioning agents for information on the need for effective contraception. Males capable of fathering a child and females of childbearing age should use an effective method of contraception from start of mobilization through at least 6 months after administration of LENMELDY. Infertility There are no data on the effects of LENMELDY on fertility. Data are available on the risk of infertility with myeloablative conditioning. In clinical trials of LENMELDY, seven children (50% of females) developed ovarian failure. Advise children of the option to cryopreserve semen or ova before treatment, if appropriate. For additional safety information, please see the full Prescribing Information. About Orchard Therapeutics Orchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment. Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist. For more information, please visit . About Kyowa Kirin Kyowa Kirin aims to discover novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients affected by a severe or rare disease. A shared commitment to our values, to sustainable growth, and to making people smile unites us across our four regions – Japan, Asia Pacific, North America, and EMEA/International. You can learn more about the business of Kyowa Kirin at . ______________________________ iMahmood et al. Metachromatic Leukodystrophy: A Case of Triplets with the Late Infantile Variant and a Systematic Review of the Literature. Journal of Child Neurology 2010, DOI: Contact Benjamin Navon +1 857-248-9454 Benjamin.Navon@orchard-tx.com

引言肝窦内皮细胞(LSECs)中的NOTCH信号调节肝纤维化，这是慢性肝脏疾病的病理特征。POFUT1是NOTCH信号的重要调节因子。2024年3月6日，西安交通大学王一东、袁祖贻及吴岳共同通讯在Journal of Hepatology（IF 26）在线发表题为“Endothelial POFUT1 controls injury-induced liver fibrosis by repressing fibrinogen synthesis”的研究论文，该研究表明内皮细胞POFUT1通过抑制纤维蛋白原合成来控制损伤性肝纤维化。POFUT1缺失促进损伤诱导的LSECs毛细血管化和HSC活化，导致肝纤维化加重。RNA-seq分析显示，POFUT1缺乏可上调LSECs中纤维蛋白原的表达。与此一致的是，肝硬化患者的LSECs中纤维蛋白原升高。与对照LSECs上清液相比，用Pofut1缺失小鼠LSECs上清液处理的HSCs表现出激活加剧，这种效应通过敲低纤维蛋白原或通过药理抑制纤维蛋白原受体信号传导而减弱，表明LSECs来源的纤维蛋白原诱导了HSCs的激活。在机制上，POFUT1缺失通过增强NOTCH/HES1/STAT3信号通路来增强纤维蛋白原的表达。总之，内皮细胞POFUT1通过抑制纤维蛋白原的表达来预防损伤性肝纤维化，而纤维蛋白原是激活造血干细胞的促纤维化旁分泌信号。针对POFUT1/NOTCH/HES1/STAT3/纤维蛋白原轴的治疗为预防和治疗纤维化性肝病提供了一种有希望的策略。肝纤维化是一种细胞病理过程，以细胞外基质蛋白(主要包括胶原蛋白)的过度积累为特征，在大多数慢性肝病中均有发生。不受控制的肝纤维化可发展为肝硬化，导致门脉高压和肝衰竭，通常需要肝移植。肝星状细胞是肝脏中产生胶原的肌成纤维细胞的主要细胞来源。在对损伤的反应中，局部的、静止的HSC在一个被称为HSC激活的过程中变得增殖和纤维化，这被认为是肝纤维化的主要驱动因素。静止的HSC被来自肝脏内邻近细胞的旁分泌信号激活，包括免疫细胞、肝细胞、胆道上皮细胞和肝窦内皮细胞(LSECs)。识别这些HSC激活信号可能为治疗纤维化肝疾病提供新的靶点。LSECs是高度特化的内皮细胞，排列在肝的窦状毛细血管上，是最丰富的非实质肝细胞群。与其他器官的一般毛细血管不同，LSECs的膜上有小孔，缺乏有组织的基底膜。这些特征促进了膜的通透性，使肝细胞与动脉和门静脉血流之间的物质直接交换成为可能。LSECs在维持肝脏稳态中发挥多种功能，包括调节血管张力、抗原呈递、抗原清除，调节肝内凝固，以及维持HSC处于静止状态。此外，LSECs产生促再生血管分泌信号，包括WNT2、WNT9和HGF，以支持肝细胞增殖促进肝脏再生。在急性或慢性损伤的反应中，LSECs经历了一种被称为毛细血管化的表型开关，并对邻近细胞产生负面影响，包括肝细胞增殖的衰减和HSC的激活，导致肝纤维化。模式图（Credit: Journal of Hepatology）蛋白O-岩藻糖基转移酶1((POFUT1)是一种酶，负责通过与表皮生长因子-样(EGF-like)重复序列中的丝氨酸或苏氨酸残基的O连锁将焦点添加到蛋白。O键的焦点可以被其他糖进一步修饰，这些修饰对蛋白质功能是必不可少的。大约100种人类蛋白质含有EGF-like重复序列，其一致序列为O-聚焦。其中，NOTCH 受体(NOTCH1-4)比数据库中的其他蛋白含有更多的EGF-Like重复序列。研究表明，在黑胃果蝇和小鼠中，由于在血管发生、心脏发生、躯体发生和神经发生方面存在严重缺陷，POFUT1的缺失会导致胚胎死亡，这些表型与NOTCH基因敲除时所见的表型相似。Pofut1和Notch1突变体之间的这种表型相似性表明Notch1可能是Pofut1的靶点。事实上，NOTCH受体的O-聚焦化对于NOTCH配体的正确结合以及下游NOTCH信号的启动至关重要。该研究使用内皮特异性缺失POFUT1的小鼠系研究了POFUT1在损伤性肝纤维化中的功能。研究结果显示，POFUT1的缺失加重了四氯化碳(CCl4)或胆管结扎(BDL) 手术引起的肝纤维化。在机制上，POFUT1缺失导致NOTCH信号升高，随后STAT3通路激活，进而诱导LSECs中的纤维蛋白原表达。与小鼠研究的观察结果一致，发现肝硬化患者LSECs中纤维蛋白原水平上调。此外，LSECs来源的纤维蛋白原促进HSC活化，从而导致肝纤维化加重。总之，该研究结果确定纤维蛋白原是LSECs产生的一种新的促纤维化旁分泌信号，可以靶向治疗纤维化性肝病。原文链接https://doi.org/10.1016/j.jhep.2024.02.032责编|探索君排版|探索君文章来源|“iNature”End往期精选围观一文读透细胞死亡(Cell Death) | 24年Cell重磅综述（长文收藏版）热文Nature | 破除传统：为何我们需要重新思考肿瘤的命名方式热文Nature | 2024年值得关注的七项技术热文Nature | 自身免疫性疾病能被治愈吗？科学家们终于看到了希望热文CRISPR技术进化史 | 24年Cell综述

2024年3月7-8日第七届成都生物医药创新者峰会展位号：B16号上海澳能生物技术有限公司总部位于上海张江药谷，是一家成立于2019年，以人原代免疫细胞实验技术的研发与服务（非临床）为核心业务的上海市高新技术企业。澳能生物建立了基于人外周血单个核细胞（PBMCs）体外实验评估肽类药物免疫原性的稳定性平台。基于肽的免疫原性评估，筛选出免疫原性风险符合法规要求的候选药物，确保药物的安全性和有效性，加速仿制药申报进程。我们的服务不仅包括技术的研发和优化，还包括对客户项目的全程跟踪与支持。我们从客户需求出发，通过深入的沟通、专业的设计和实施，确保客户项目的顺利进行和目标的顺利实现。我们以高水准的团队、专业的技术、精细的服务，向客户提供优质的解决方案。质量管理体系公司建立了完善的生产及药效服务质量管理体系，真正做到全过程控制，规范影响质量的各个环节，用高质量标准的产品及服务助力科学研究。业务板块原代细胞 分离 / 分选 / 分化 / 置换 服务人——LeukoPak、PBMC、T / B / NK / Monocyte、DC（iDC / mDC / pDC）、Macrophage（MDM / M1 / M2）、Treg、TCR  γδT、Neutrophil、CD34+ HSC、Naive CD4+ T、Naive CD8+ T...实验动物细胞——小鼠、大鼠、猴、狗、猪、兔等其他——血清、血浆、红细胞、血小板等技术服务肿瘤免疫功能实验体外服务ADCC、ADCP、CDC、MLR、Transwell、细胞活化 / 杀伤 / 分化 / 诱导...检测服务细胞流式、EliSpot、Luminex多因子检测体内服务PBMC / HSC人源化小鼠模型免疫原性评价多肽类仿制药物免疫原性风险评价先天免疫、获得性免疫创新药物免疫原性评价DC / T cell assay、Response index assessment志愿者库合规采集所有志愿者在采集前皆会通过26项血常规、4项病毒检测（丙肝、乙肝、梅毒、HIV）所有志愿者的年龄低于50岁，且健康状态正常，无慢性疾病，3个月内无采集记录所有志愿者都签署知情同意书所有采集都通过专业的采集团队进行所有耗材和采集仪器具有可追溯性完整信息目前在库登记志愿者数超1000人，并持续增加HLA基因分型：HLA-A、HLA-B、HLA-C、HLA-DRB1、HLA-DQB1血型：ABO、Rh±细胞亚型比例：CD3+、CD4+、CD8+、CD14+、CD16+、CD19+、CD56+、PD-1+基础信息：身高、体重、年龄、吸烟与否澳能优势近百种原代免疫的细胞分离 / 分选 / 诱导分化服务千人庞大Donor库，严格健康情况筛选完善质量管理体系，保证每一次服务都达到统一水平合规采集，让您无后顾之忧可控运输，看得见的温度，看得见的放心提供COA - Donor基础信息 / 流式数据 / 细胞质量检测结果多种预筛选服务 - ADCC / TDCC / MLR / SEB / PD-1 / 体内重建可承接免疫学实验项目，专业、高效、实惠上海澳能生物技术有限公司提供健康人外周原代细胞、动员外周原代细胞、脐血原代细胞的分离及分选服务；免疫药效实验材料筛选服务；承接免疫学体内外药效评价项目。通过先进的研发生产技术及完善的质量管理体系，真正做到细胞生产及药效服务各环节的全过程控制，为国内各生物制药及细胞治疗企业、CRO、CMO、CDMO、科研院所、生物技术公司等众多合作伙伴，提供高质量的产品和标准化的服务，助力中国生命科学研究领域的发展。微信号：OriBiotech澳能电话：021-51915688官网：www.oribiotech.cn邮箱：info@oribiotech.cn*报名通道限时免费，现在就报名抢占席位关于药融圈药融圈PRHub旨在帮助生物医药科技型企业进行品牌推广及商务拓展服务，针对客户的真实需求制定系统化解决方案，通过“翻译-降维-场景化”将客户的品牌信息以直白易懂的方式被公众知悉，同时在流量渠道覆盖100万+垂直用户基础上实现合作目的，帮助合作伙伴完成从品牌开始到商务为终的闭环营销服务。我们已经完成了数十场线下1000人规模的生物医药研发类会议，涵盖小分子新药，大分子新药，改良型新药，BD跨境交易等领域，品牌会议包括中国国际生物及化学制药产业大会(6000人以上)，仿制药峰会（600人以上），新药创新者系列峰会（1200人以上），服务了百余家上市/独角兽/生物技术/制药企业。